Growth Modulation in the Treatment of Idiopathic Scoliosis Using the REFLECT™ Scoliosis Correction System

Overview

About this study

The purpose of this multi-center, prospective, single-arm registry Post-Approval Study (PAS) is to evaluate the radiographic and clinical outcomes of 100 patients with idiopathic scoliosis treated with the REFLECT™ Scoliosis Correction System, as a condition of HDE approval.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Diagnosis of progressive idiopathic scoliosis.
  • Preoperative major Cobb angle 30°-65°.
  • Preoperative flexibility to ≤ 30° on side bending radiograph (left or right).
  • Skeletally immature at the time of surgery with Risser sign < 5 or Sanders score < 8.
  • Osseous structure dimensionally adequate to accommodate screw fixation, as determined by radiographic imaging.
  • Failed or intolerant to bracing.
  • Signed informed consent and/or assent forms specific to this study.

Exclusion Criteria:

  • Prior spinal surgery at the level(s) to be treated.
  • Documented poor bone quality, defined as a T-score of -1.5 or less.
  • Presence of any systemic infection, local infection, or skin compromise at the surgical site P.
  • Any medical or surgical condition which would preclude the potential benefit of spinal surgery, such as coagulation disorders, allergies to the implant materials, and patient's unwillingness or inability to cooperate with post-operative care instructions.
  • Unwillingness, inability, or living situation (e.g. custody arrangements, homelessness, detention) that would preclude ability to return to the study site for follow-up visits as described in protocol and Informed Consent.
  • Active participation in a drug or device study that is more than minimal risk such that participation would confound the measurements of the present study.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/11/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Annalise Larson, M.D.

Open for enrollment

Contact information:

Angela Severson

(507) 538-3560

Severson.Angela2@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20562144

Mayo Clinic Footer